G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas With Intact 1p/19q Chromosomes
Latest Information Update: 20 May 2022
At a glance
- Drugs Nibrozetone (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- Acronyms G-FORCE-1
- Sponsors EpicentRx
- 12 May 2022 Status changed from active, no longer recruiting to completed.
- 21 Jul 2020 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
- 25 Nov 2019 According to an EpicentRx media release, the late-breaking data (n=18) from this study were presented on 22 Nov 2019 at the Society for Neuro-Oncology annual meeting in Phoenix.